Moshe Inbar

12.1k total citations · 1 hit paper
171 papers, 3.7k citations indexed

About

Moshe Inbar is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Moshe Inbar has authored 171 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 98 papers in Oncology, 70 papers in Pulmonary and Respiratory Medicine and 33 papers in Surgery. Recurrent topics in Moshe Inbar's work include Cancer Treatment and Pharmacology (36 papers), Ovarian cancer diagnosis and treatment (23 papers) and Sarcoma Diagnosis and Treatment (21 papers). Moshe Inbar is often cited by papers focused on Cancer Treatment and Pharmacology (36 papers), Ovarian cancer diagnosis and treatment (23 papers) and Sarcoma Diagnosis and Treatment (21 papers). Moshe Inbar collaborates with scholars based in Israel, United States and Austria. Moshe Inbar's co-authors include Nely Wigler, Ofer Merimsky, Samario Chaitchik, Raphael Catane, Craig Tendler, Stephen P. Ackland, D G Kieback, Piotr Tomczak, Eva‐Maria Grischke and F. Orlandi and has published in prestigious journals such as Journal of Clinical Oncology, Gastroenterology and JNCI Journal of the National Cancer Institute.

In The Last Decade

Moshe Inbar

168 papers receiving 3.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl(CAELYX™/Doxil®) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancer

2004 1.3k citations E O’Brien, Nely Wigler et al. Annals of Oncology profile →

Peers

Countries citing papers authored by Moshe Inbar

Since Specialization

Citations

This map shows the geographic impact of Moshe Inbar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Moshe Inbar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Moshe Inbar more than expected).

Fields of papers citing papers by Moshe Inbar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Moshe Inbar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Moshe Inbar. The network helps show where Moshe Inbar may publish in the future.

Co-authorship network of co-authors of Moshe Inbar

This figure shows the co-authorship network connecting the top 25 collaborators of Moshe Inbar. A scholar is included among the top collaborators of Moshe Inbar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Moshe Inbar. Moshe Inbar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Regional Nodal Irradiation After Breast Conserving Surgery for Early HER2-Positive Breast Cancer: Results of a Subanalysis From the ALTTO Trial 2016 ·JNCI Journal of the National Cancer Institute ·Isabelle Gingras, Eileen Holmes, Evandro de Azambuja, David H. Nguyen, Miguel Izquierdo, Jo Anne Zujewski, Moshe Inbar, Bjørn Naume, Gianluca Tomasello, Julie R. Gralow, Antonio C. Wolff, Lyndsay N. Harris, Michael Gnant, Alvaro Moreno‐Aspitia, Martine Piccart, Hatem A. Azim	19
2	Phase III study of Palbociclib in combination with Exemestane vs. Capecitabine, in Hormonal Receptor (HR) positive/HER2 negative Metastatic Breast Cancer (MBC) patients with Resistance to non-steroidal Aromatase inhibitors (NSAI): PEARL study (GEICAM/2013-02_CECOG/BC.1.3.006) 2015 ·Journal of Clinical Oncology ·Miguel Martín, Moshe Inbar, Eva Carrasco, István Láng, M.J. Escudero, Zsuzsanna Kahán, Cynthia Huang Bartlett, Begoña Bermejo, (unknown), José Ignacio Chacón, Zanete Zvirbule, José Á. García-Sáenz, Juan de la Haba-Rodríguez, María Koehler, Miguel Gil‐Gil, Eva María Ciruelos Gil, Montserrat Muñoz-Mateu, Serafín Morales, José Luis Alonso-Romero, Christoph Zielinski	1
3	Predictive role of hand–foot syndrome in patients receiving first-line capecitabine plus bevacizumab for HER2-negative metastatic breast cancer 2015 ·British Journal of Cancer ·Christoph Zielinski, István Láng, S. Beslija, Zsuzsanna Kahán, Moshe Inbar, Salomon M. Stemmer, (unknown), Damir Vrbanec, Diethelm Messinger, Thomas Brodowicz	21
4	Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses 2014 ·British Journal of Cancer ·Thomas Brodowicz, István Láng, Zsuzsanna Kahán, Richard Greil, S. Beslija, Salomon M. Stemmer, Bella Kaufman, Luboš Petruželka, Alexandru Eniu, (unknown), Krassimir Koynov, D. Vrbanec, Tadeusz Pieńkowski, Bohuslav Melichar, S. Špánik, (unknown), Diethelm Messinger, Moshe Inbar, Christoph Zielinski	24
5	Improved Treatment of the Breast and Supraclavicular Fossa Based on a Simple Geometrical Principle 2011 ·Medical dosimetry ·(unknown), Benjamin W. Corn, (unknown), (unknown), (unknown), (unknown), Moshe Inbar, Ilan G. Ron, (unknown), (unknown)	4
6	Fulvestrant in heavily pretreated metastatic breast cancer: is it still effective as a very advanced line of treatment? 2008 ·PubMed ·Tamar Safra, Julia Greenberg, Ilan G. Ron, Rami Ben‐Yosef, Moshe Inbar, David Sarid, Neora Yaal‐Hahoshen	3
7	Decreased prevalence of asymptomatic choroidal metastasis in disseminated breast and lung cancer: argument against screening 2006 ·British Journal of Ophthalmology ·(unknown), Meira Neudorfer, Gad Heilweil, Ofer Merimsky, (unknown), Moshe Inbar, Neora Yaal‐Hahoshen	34
8	ErbB4 increases the proliferation potential of human lung cancer cells and its blockage can be used as a target for anti‐cancer therapy 2006 ·International Journal of Cancer ·Alex Starr, Joel Greif, Akiva Vexler, (unknown), (unknown), Chanan Rubin, (unknown), Sylvia Marmor, Shahar Lev‐Ari, Moshe Inbar, Yosef Yarden, Rami Ben‐Yosef	53
9	Targeting pulmonary metastases of renal cell carcinoma by inhalation of interleukin-2 2004 ·Annals of Oncology ·Ofer Merimsky, (unknown), Rony Weitzen, (unknown), (unknown), (unknown), Tamar Peretz, Menachem Ben-Shahar, Haim Biran, (unknown), (unknown), David Loven, (unknown), Avivit Neumann, (unknown), Moshe Inbar	22
10	Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl(CAELYX™/Doxil®) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancer breakdown → 2004 ·Annals of Oncology ·E O’Brien, Nely Wigler, Moshe Inbar, R. Rosso, Eva‐Maria Grischke, Armando Santoro, Raphael Catane, D G Kieback, Piotr Tomczak, Stephen P. Ackland, F. Orlandi, L. Mellars, Leila Alland, Craig Tendler	1311
11	CMF (Cyclophosphamide, Methotrexate, 5-Fluorouracil) Versus CNF (Cyclophosphamide, Mitoxantrone, 5-Fluorouracil) as Adjuvant Chemotherapy for Stage II Lymph-Node Positive Breast Cancer 2002 ·American Journal of Clinical Oncology ·Ilan G. Ron, Nely Wigler, Riva Borovik, Tamar Peretz, Shulamith Rizel, Adi Shani, Joseph Brenner, (unknown), Harold J. Brenner, Samario Chaitchik, Raphael Catane, Moshe Inbar	1
12	CMF (Cyclophosphamide, Methotrexate, 5-Fluorouracil) Versus CNF (Cyclophosphamide, Mitoxantrone, 5-Fluorouracil) as Adjuvant Chemotherapy for Stage II Lymph-Node Positive Breast Cancer 2001 ·American Journal of Clinical Oncology ·Ilan G. Ron, Nely Wigler, Riva Borovik, G Brufman, Shulamith Rizel, Adi Shani, Joseph Brenner, (unknown), (unknown), Moshe Inbar, Harold J. Brenner, Samario Chaitchik, Raphael Catane	7
13	Choriocarcinoma Arising in a Squamous Cell Carcinoma of the Esophagus 2000 ·American Journal of Clinical Oncology ·Ofer Merimsky, (unknown), Noam Asna, Einat Shmueli, (unknown), Moshe Inbar	7
14	Vinorelbine-related acute cardiopulmonary toxicity 1999 ·Cancer Chemotherapy and Pharmacology ·(unknown), (unknown), (unknown), Moshe Inbar	10
15	Primary Liposarcoma of the Mediastinum 1998 ·Sarcoma ·Joel Greif, S. Marmor, Ofer Merimsky, (unknown), Moshe Inbar	8
16	The effects of tamoxifen treatment on the endometrium 1996 ·Fertility and Sterility ·Edward E. Wallach, Yair Daniel, Moshe Inbar, Amiram Bar‐Am, M. Reuben Peyser, Joseph B. Lessing	36
17	Regional perfusion with hemofiltration (chemofiltration) for the treatment of patients with regionally advanced cancer 1996 ·Cancer ·Mordechai Gutman, (unknown), Patrick Sorkine, Moshe Inbar, Dina Lev, (unknown), (unknown), Samario Chaitchik, Joseph M. Klausner	3
18	Kaposi's Sarcoma on a Lymphedematous Arm After Mastectomy 1996 ·American Journal of Clinical Oncology ·Ilan G. Ron, Gail Amir, (unknown), Samario Chaitchik, Moshe Inbar	8
19	Endometrioid carcinoma of the ovary presenting as primary carcinoma of the breast 1992 ·Acta Obstetricia Et Gynecologica Scandinavica ·(unknown), Moshe Inbar, Marisa Halpern, Samario Chaitchik	6
20	Interferon-related mental deterioration and behavioral changes in patients with renal cell carcinoma 1990 ·European Journal of Cancer and Clinical Oncology ·Ofer Merimsky, Irith Reider‐Groswasser, Moshe Inbar, Samario Chaitchik	36

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact